← Product Code LFD · K991938

# CAPHOSOL ARTIFICIAL SALIVA (K991938)

_Inpharma A.S. · LFD · Aug 10, 1999 · DE · SESE_

**Canonical URL:** https://fda.innolitics.com/device/K991938

## Device Facts

- **Applicant:** Inpharma A.S.
- **Product Code:** LFD
- **Decision Date:** Aug 10, 1999
- **Decision:** SESE
- **Submission Type:** Traditional
- **Device Class:** Class U
- **Review Panel:** DE
- **Attributes:** Therapeutic

## Intended Use

Caphosol is indicated for dryness of the mouth or throat (hyposalivation, xerostomia), regardless of the cause and regardless of whether the condition is temporary or permanent. Caphosol is indicated for relief of dryness of the oral mucosa when hyposalivation results from the following: surgery, radiotherapy near the salivary glands, chemotherapy, infection or dysfunction of the salivary glands; inflammation of the mouth or throat; fever; emotional factors such as fear or anxiety, obstruction of the salivary ducts, Sjögren's syndrome; and Bell's Palsy. Caphosol is also indicated for dryness of the oral mucosa due to drugs such as antihistamines or atropine or other anticholinergic agents that suppress salivary secretion. It may be used as part of an oral hygiene program for patients with dry mouth. Caphosol provides intensive hygiene of the oral cavity, and may be used to help relieve bad taste and to relieve offensive nasal discharge and crusting.

## Device Story

Caphosol is an artificial saliva product consisting of two separate solutions, Caphosol A (phosphate) and Caphosol B (calcium). The solutions are mixed by the patient or caregiver and applied to the oral cavity. The device functions as a topical oral rinse to provide moisture and hygiene for the oral mucosa. It is used to relieve symptoms of dry mouth and throat, including bad taste and nasal crusting, regardless of the underlying cause. The device is intended for use as part of an oral hygiene program.

## Clinical Evidence

No clinical data provided; bench testing only.

## Technological Characteristics

Artificial saliva consisting of two aqueous solutions: Caphosol A (phosphate solution) and Caphosol B (calcium solution). The device is a liquid oral rinse. No specific materials, energy sources, or software components are described.

## Predicate Devices

- GLANDOSANE (SALIVART®), Synthetic Saliva ([K874106](/device/K874106.md))

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}------------------------------------------------

AUG 10 1999

K97 1938

# 510(k) SUMMARY Inpharma Pharmaceuticals, Inc. CaphosoITM Artificial Saliva

Submitters Information

| Inpharma A.S.  |  |
|----------------|--|
| Industraten 15 |  |
| 3400 Lier      |  |
| Norway         |  |
| Contact:       |  |
| Telephone:     |  |

Dr. Björn Th. Johansen +41 32 84 87 60

Date Prepared

June 7, 1999

### Name of Device

Caphosol™ Artificial Saliva Consisting of a mixture of two solutions Caphosol™ A -- 15 mL Phosphate Solution and Caphosol™ B - 15 mL Calcium Solution

## Classification Name

Artificial Saliva

Predicate Devices

GLANDOSANE (SALIVART®), Synthetic Saliva, 510(k) Notification K874106, decision date April 15, 1988, applicant was Fresenius, USA, Inc., currently distributed by Gebauer Company, Cleveland, Ohio.

{1}------------------------------------------------

Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized image of an eagle or bird-like figure with three curved lines representing its body and head. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the image.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

AUG 10 1999

Inpharma A.S. c/o Mr. Bruce R. Manning President New England Biomedical Research, Incorporated 27 South Street P.O. Box 809 Northborough, Massachusetts 01532

Re : K991938 Caphosol™ Artificial Saliva Trade Name: Unclassified Regulatory Class: Product Code: LFD Dated: June 9, 1999 Received: June 9, 1999

Dear Mr. Manning:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions The general controls provisions of the Act of the Act. include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major requlations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) requlation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP requlation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{2}------------------------------------------------

Page 2 - Mr. Manning

this response to your premarket notification Please note: submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4692. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to
premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at
its internet address "http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,

Timothy A. Ulatowski
Director

Directbr Division of Dental, Infection Control, and General Hospital Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

510(k) Number (if known):

CAPHOSOL™, Artificial Saliva Device Name:

#### Indications For Use:

Caphosol is indicated for dryness of the mouth or throat (hyposalivation, xerostomia), regardless of the cause and regardless of whether the condition is temporary or permanent.

Caphosol is indicated for relief of dryness of the oral mucosa when hyposalivation results from the following: surgery, radiotherapy near the salivary glands, chemotherapy, infection or dysfunction of the salivary glands; inflammation of the mouth or throat; fever; emotional factors such as fear or anxiety, obstruction of the salivary ducts, Sjögren's syndrome; and Bell's Palsy.

Caphosol is also indicated for dryness of the oral mucosa due to drugs such as antihistamines or atropine or other anticholinergic agents that suppress salivary secretion.

It may be used as part of an oral hygiene program for patients with dry mouth. Caphosol provides intensive hygiene of the oral cavity, and may be used to help relieve bad taste and to relieve offensive nasal discharge and crusting.

# (PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

| Prescription Use     |  |
|----------------------|--|
| (Per 21 CFR 801.109) |  |

OR

Over-The-Counter Use

6

Sindre L. Shine, D MD, MP for MSR

(Division Sign-Off) Division of Dental, Infection Control, and General Hospital Device 510(k) Number

---

**Source:** [https://fda.innolitics.com/device/K991938](https://fda.innolitics.com/device/K991938)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com